LDN for POTS and Dysautonomia: Heart Rate, Fatigue, and Where GLP-1s Fit
Low-dose naltrexone, often called LDN, is discussed in POTS and dysautonomia communities as a possible option for pain, fatigue, brain fog, or broader autonomic symptoms. Interest is understandable. These conditions can be disabling, symptoms often overlap, and treatment commonly requires several strategies rather than one medication.
The evidence, however, is much smaller than the online conversation.
A published POTS case series reviewed only six patients. Three reported feeling that their POTS improved, two stopped LDN because they did not perceive benefit, and standardized patient-reported measures changed inconsistently. A later retrospective chart review included 29 people with dysautonomia and found no statistically significant improvement in average total or subsection COMPASS-31 autonomic symptom scores after LDN. Seven patients had documented pain improvement, but that does not prove improvement in POTS itself. These reports cannot establish that LDN lowers standing heart rate, prevents fainting, or treats the underlying causes of dysautonomia.
The short answer
LDN is an off-label option that a clinician may consider for selected symptoms or overlapping pain conditions. It is not an FDA-approved treatment for POTS, and current evidence does not show that it reliably controls orthostatic tachycardia or replaces established POTS care.
For someone also considering semaglutide, tirzepatide, or another GLP-1-based medication, the goals should remain separate. GLP-1 therapy may be appropriate for an approved obesity, diabetes, cardiovascular, sleep apnea, or metabolic indication, depending on the specific drug. It is not a proven POTS treatment. Gastrointestinal fluid loss, reduced intake, dizziness, blood-pressure changes, and heart-rate effects may complicate dysautonomia and deserve a coordinated monitoring plan.
Considering LDN? Scripx can help you understand personalized compounded low-dose naltrexone optionsafter a licensed prescriber determines that treatment is appropriate. LDN is off-label for POTS and should not replace diagnostic evaluation or established care.
Ready to Get Started?
Explore available treatment options and complete a secure health questionnaire for provider review.
View Products & Start Your Order →Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.
What POTS is, and what it is not
Postural orthostatic tachycardia syndrome, or POTS, is a form of chronic orthostatic intolerance. Symptoms become worse while upright and generally improve when a person lies down. Common symptoms include palpitations, lightheadedness, fatigue, brain fog, exercise intolerance, tremulousness, nausea, and sometimes fainting.
In adults, clinical guidance generally requires a sustained heart-rate increase of at least 30 beats per minute within 10 minutes of standing or head-up tilt. For people ages 12 through 19, the threshold is at least 40 beats per minute. Symptoms should be present for at least three months, significant orthostatic hypotension should be absent, and another condition should not explain the tachycardia.
That last point matters. Dehydration, anemia, blood loss, fever, endocrine disorders, prolonged bed rest, medication effects, and some cardiac rhythm disorders can produce similar symptoms or a rapid pulse. A smartwatch reading alone cannot diagnose POTS.
POTS is also heterogeneous. Neuropathic, hyperadrenergic, hypovolemic, post-viral, autoimmune, and deconditioning-related features may overlap in the same person. A plausible theory about one pathway does not prove that a medication treats the whole syndrome.
What LDN is
Naltrexone is an opioid receptor antagonist approved at conventional doses for alcohol and opioid use disorders. “Low-dose naltrexone” describes prescribing substantially lower doses for off-label purposes. There is no single FDA-approved LDN product or FDA-approved LDN dosing schedule for POTS.
Proposed explanations for LDN include temporary opioid receptor blockade and effects on neuroimmune signaling. These mechanisms are hypotheses, not clinical proof that LDN normalizes autonomic function, lowers standing heart rate, expands blood volume, or prevents syncope.
Compounding may allow a prescriber to select a dosage form, strength, or inactive-ingredient profile that is not available as a commercial tablet. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. Learn more about personalized compounding.
What the direct evidence actually shows
A six-patient POTS case series
A 2023 case series reviewed six patients with POTS who received LDN. Three reported improvement after starting treatment. Two stopped because they did not perceive benefit. Standardized measures of fatigue, physical and mental health, anxiety, depression, and autonomic symptoms showed inconsistent changes, with improvement or stability in some patients and worsening in others.
This report is useful for generating a research question. It is not a randomized trial, did not include a placebo group, and was far too small to estimate how often LDN helps. Patient-reported improvement is important, but it cannot establish a direct effect on POTS when symptoms fluctuate and other care may change.
A 29-patient dysautonomia chart review
A 2025 retrospective chart review evaluated 29 patients diagnosed with general dysautonomia, POTS, or stiff person syndrome. Pain or fibromyalgia was the most common reason for prescribing LDN, followed by orthostatic intolerance. Seven patients had documented pain improvement. Five reported mild side effects.
The key result was negative: average COMPASS-31 total and subsection scores did not improve to a statistically significant degree between the LDN prescription visit and follow-up three to nine months later. Because the group combined different diagnoses, lacked a control arm, and relied on clinical records, it cannot establish efficacy or rule out benefit for a carefully selected individual. It does show why broad claims that LDN “treats dysautonomia” go beyond the data.
A registered POTS fatigue trial
A placebo-controlled study has been registered to test whether LDN reduces fatigue in POTS. A registered or recruiting trial signals scientific interest, not a positive result. Until results are completed, analyzed, and published, it cannot support an efficacy claim.
A multi-treatment case report
One published case described improvement in a patient with severe POTS and mast cell activation syndrome who received LDN along with intravenous immunoglobulin and antibiotic therapy. Because several interventions were introduced, the report cannot isolate the effect of LDN. One complex case is not evidence of a typical response.
Evidence snapshot
| Evidence question | What has been reported | What remains unproven |
|---|---|---|
| Direct POTS evidence | A six-patient case series reported mixed outcomes | Reliable improvement in heart rate, fatigue, brain fog, or function |
| Broader dysautonomia evidence | A 29-patient chart review found pain improvement documented in seven patients | A statistically significant average improvement in autonomic symptom burden |
| Randomized trial | A placebo-controlled POTS fatigue study is registered | Trial-confirmed efficacy or an established POTS dosing strategy |
| Heart-rate control | No direct controlled evidence shows LDN lowers orthostatic heart rate | Prevention of tachycardia, presyncope, or syncope |
| Disease modification | Neuroimmune and inflammatory hypotheses exist | Correction of autonomic dysfunction or an autoimmune cause |
| Long COVID crossover | POTS and autonomic symptoms can occur after COVID-19 | That LDN specifically treats post-COVID POTS |
| GLP-1 crossover | An approved GLP-1 medicine may address a separate metabolic indication | GLP-1 therapy as a POTS treatment |
| LDN plus GLP-1 | Both may be prescribed for separate goals after individualized review | A proven combination for POTS, fatigue, pain, or enhanced weight loss |
Fatigue, brain fog, pain, and heart rate are different outcomes
POTS is measured through both symptoms and objective findings. A person may have less pain yet no change in standing heart rate. Fatigue may improve without better orthostatic tolerance. Brain fog may change because sleep, hydration, nutrition, migraine, medications, or post-exertional symptoms changed.
That is why a treatment trial should define the target before it begins. Useful questions include:
-
Is the goal less widespread pain?
-
Is the goal longer standing or walking time?
-
Is the goal fewer episodes of presyncope?
-
Is the goal better fatigue or cognitive function?
-
Is the goal a lower standing heart rate?
These outcomes should not be treated as interchangeable. A clear target makes it easier to distinguish meaningful benefit from day-to-day fluctuation.
POTS and Long COVID can overlap
Autonomic dysfunction is recognized in some people with Long COVID, and POTS may develop after SARS-CoV-2 infection. Fatigue, brain fog, palpitations, dizziness, and exercise intolerance can occur in both conditions.
The overlap does not mean every person with Long COVID has POTS, or that every person with POTS has Long COVID. It also does not mean a treatment discussed for one condition is proven for the other. People with symptoms after COVID-19 still need an evaluation for competing explanations, especially when chest pain, shortness of breath, fainting, anemia, thyroid disease, medication effects, or an arrhythmia could be involved.
For a deeper review of that intersection, see LDN for Long COVID, fatigue, and brain fog.
What established POTS management looks like
POTS treatment is individualized and usually combines non-drug strategies with symptom-directed medication when needed. Clinical guidance commonly begins with attention to fluid and sodium intake when medically appropriate, compression garments, and gradual recumbent or semi-recumbent exercise. These steps require modification for people with kidney disease, heart failure, hypertension, eating disorders, or other conditions in which aggressive fluid or sodium intake could be unsafe.
Depending on the person’s heart rate, blood pressure, symptoms, and subtype, a clinician may consider medications that reduce heart rate, improve vascular tone, or support blood volume. No single medicine works for every patient. LDN should not displace a diagnostic workup or a care plan designed around the patient’s hemodynamics.
If a clinician recommends an LDN trial
An off-label trial should be structured enough to answer whether it helped. Before treatment, document the target symptom and a practical baseline. The plan may include:
-
Upright symptoms and functional limits
-
Clinician-directed supine and standing heart rate and blood pressure
-
Fainting or near-fainting frequency
-
Fatigue, brain fog, pain, sleep, and gastrointestinal symptoms
-
Fluid and sodium plan, when appropriate
-
New medications, dose changes, illness, menstrual cycle effects, and heat exposure
-
A follow-up date and a pre-agreed stopping rule
Change one major variable at a time when feasible. Starting LDN and increasing a GLP-1 medicine during the same week may make nausea, appetite changes, sleep disruption, dizziness, or fatigue difficult to attribute.
Possible LDN effects reported in broader use can include vivid dreams, insomnia, headache, nausea, or gastrointestinal upset. A prescriber should review liver history, pregnancy considerations, current medications, and the reason for using a compounded preparation.
The opioid interaction is the major safety checkpoint
Naltrexone blocks opioid receptors. Prescribing information lists opioid analgesic use and current opioid dependence as contraindications, and naltrexone can precipitate withdrawal. Opioids may also be less effective while naltrexone is active.
Tell every prescriber, surgeon, dentist, emergency clinician, and pharmacist that you take LDN. This is especially important before a planned procedure, after an injury, or when cough, diarrhea, or pain products may contain an opioid. Do not stop LDN or attempt an opioid washout on your own. The timing and pain-management plan should come from the treating clinicians.
Read the full Scripx guide to LDN drug interactions, opioids, and GLP-1s and the overview of LDN side effects.
Where GLP-1 medicines fit
Semaglutide and tirzepatide have approved uses tied to specific metabolic and cardiometabolic indications. They do not have an FDA-approved indication for POTS or dysautonomia.
The issue is not a known universal prohibition against combining LDN with every GLP-1 medicine. The issue is that direct combination evidence in POTS is absent, while GLP-1 effects can overlap with symptoms clinicians are trying to monitor.
Current Wegovy prescribing information lists nausea, diarrhea, vomiting, constipation, fatigue, and dizziness among common adverse reactions. It warns about acute kidney injury due to volume depletion and instructs clinicians to monitor heart rate at regular intervals. It also delays gastric emptying, which can affect some oral medicines.
Current Zepbound labeling likewise emphasizes gastrointestinal adverse effects and kidney injury due to volume depletion. Hypotension, including orthostatic hypotension, has been reported, and the label notes an association with gastrointestinal adverse events and dehydration.
For someone with POTS, these are not abstract label details. Reduced appetite can mean less fluid and sodium intake. Vomiting or diarrhea can reduce circulating volume. Dizziness or fatigue can look like a POTS flare. A heart-rate increase can complicate interpretation of an existing tachycardia syndrome.
If a GLP-1 medicine is appropriate for a separate indication, the care plan may include slower clinical reassessment, active review of fluid intake and gastrointestinal losses, blood-pressure and heart-rate monitoring, and clear instructions for persistent vomiting, inability to maintain fluids, fainting, or worsening orthostatic symptoms. Dose decisions belong to the prescriber.
Learn about Scripx weight-management care.
LDN plus a GLP-1 is not a proven POTS combination
There are no adequate controlled trials showing that LDN plus semaglutide or tirzepatide improves POTS, lowers standing heart rate, prevents fainting, reduces fatigue, or produces more weight loss than appropriately prescribed GLP-1 therapy alone.
If both are prescribed, each should have its own indication, target outcome, monitoring plan, and stop criteria. A patient should know which clinician is coordinating the full medication list.
What about retatrutide?
Retatrutide is not FDA-approved. FDA states that retatrutide has not been found safe and effective for any condition and cannot be used in compounding under federal law. Products sold as “research use only” or marketed directly to consumers do not become legitimate patient-specific treatments because they are available online.
There is no clinical evidence establishing retatrutide as a treatment for POTS or showing that retatrutide plus LDN treats dysautonomia. Patients should not use an unapproved retatrutide product as a shortcut around an evidence-based evaluation.
When symptoms need prompt evaluation
Seek urgent medical care for new or severe chest pain, severe shortness of breath, fainting with injury, signs of stroke, a sustained irregular heartbeat, severe dehydration, blood in vomit or stool, or an inability to keep fluids down. New tachycardia should not automatically be labeled as POTS.
Questions to ask a prescriber
-
What diagnosis or symptom is LDN intended to address?
-
What evidence applies to someone with my POTS pattern and other conditions?
-
How will we measure benefit separately for pain, fatigue, function, and standing heart rate?
-
Could another condition or medication be causing my tachycardia?
-
Do any of my medicines contain an opioid or affect blood pressure, heart rate, or hydration?
-
What should I do before dental work, surgery, or emergency pain treatment?
-
If I use a GLP-1 medicine, how should we monitor intake, gastrointestinal losses, blood pressure, and heart rate?
-
When should I pause a medication, call the clinic, or seek urgent care?
-
When will we decide whether the trial has helped enough to continue?
Bottom line
LDN is scientifically interesting, but interest is not the same as proof. A six-patient case series produced mixed results, and a 29-patient dysautonomia chart review found no statistically significant improvement in average autonomic symptom scores. LDN has not been shown to reliably lower standing heart rate, prevent fainting, or modify POTS.
Some clinicians may still consider an individualized off-label trial, particularly when pain or an overlapping condition is part of the treatment goal. That decision should preserve established POTS care, address opioid conflicts, and use defined outcomes.
GLP-1 therapy belongs in a separate lane. It may be appropriate for an approved metabolic indication, but it is not a POTS treatment. In dysautonomia, nausea, fluid loss, reduced intake, dizziness, blood-pressure changes, and heart-rate effects require extra attention.
Ready for a clinician-guided conversation? Explore personalized LDN options, review Scripx weight-management care, or contact Scripx. Treatment requires individualized review, and no outcome is guaranteed.
Medical disclaimer
This article is for educational purposes only and is not medical advice. It does not diagnose POTS or recommend a particular medication, dose, fluid plan, or sodium target. Do not start, stop, or change prescription treatment without a qualified clinician.
FAQ Section
Does low-dose naltrexone help POTS?
The evidence is insufficient. A six-patient case series reported mixed outcomes, and a 29-patient dysautonomia chart review found no statistically significant improvement in average autonomic symptom scores. Some individuals may report improvement in pain or other symptoms, but controlled research is needed.
Does LDN lower standing heart rate?
No adequate controlled evidence shows that LDN reliably lowers orthostatic heart rate. Feeling better does not necessarily mean the objective heart-rate response has changed.
Is LDN FDA-approved for POTS or dysautonomia?
No. LDN is an off-label use of naltrexone, and there is no FDA-approved LDN product or dosing schedule for POTS.
Can LDN help POTS fatigue or brain fog?
That remains unproven. A registered placebo-controlled study is designed to evaluate fatigue, but registration does not equal a positive result. Existing observational reports are too small and inconsistent to establish benefit.
Can POTS happen after COVID-19?
Yes. POTS and other forms of autonomic dysfunction have been reported after COVID-19. Long COVID and POTS overlap, but they are not interchangeable diagnoses.
Can someone take LDN with semaglutide or tirzepatide?
There is no established POTS-specific combination protocol. A prescriber may decide both are appropriate for separate goals after reviewing the full medication list, opioid exposure, hydration, gastrointestinal symptoms, blood pressure, and heart rate.
Can GLP-1 medicines worsen POTS symptoms?
They can produce effects that may worsen or resemble a flare in some people, including nausea, vomiting, diarrhea, reduced intake, dizziness, volume depletion, blood-pressure changes, and heart-rate increase. Individual monitoring is important.
Does a GLP-1 medicine treat POTS?
No approved GLP-1 medicine is indicated to treat POTS. It may be prescribed for a separate approved metabolic or cardiometabolic indication.
Is retatrutide an option for POTS?
No evidence establishes retatrutide for POTS. It is not FDA-approved, and FDA states that it cannot be used in compounding under federal law.
Why are opioids a concern with LDN?
Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and precipitate withdrawal in an opioid-dependent person. Every treating clinician should know about LDN before prescribing pain medicine or planning a procedure.